Taken together, these results strongly suggest that inflammation reduces the expression of PPARα and PPARγ in myeloid cells of MS patients, and that PPARγ is most susceptible to the inhibitory impact of inflammatory mediators. This evidence concerns the gene PPARA and myeloid sarcoma.